Abacavir/lamivudine/zidovudine

Abacavir/lamivudine/zidovudine
Combination of
Abacavir sulfate	Nucleoside analogue reverse transcriptase inhibitor
Lamivudine	Nucleoside analogue reverse transcriptase inhibitor
Zidovudine	Nucleoside analogue reverse transcriptase inhibitor
Clinical data
Trade names	Trizivir
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a616051
License data	US DailyMed: Trizivir;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	J05AR04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: Schedule IV; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	136470-78-5 ;
PubChem CID	468908;
ChemSpider	21106400 ;
KEGG	D10838 ;
NIAID ChemDB	058986;
	(what is this?) (verify)

Abacavir/lamivudine/zidovudine, sold under the brand name Trizivir, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:

abacavir sulfate (ABC)
lamivudine (3TC)
zidovudine (AZT or ZDV)

It is indicated in the treatment of AIDS/HIV-1. For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.

The most common effects include headache and nausea (feeling sick).

Abacavir/lamivudine/zidovudine was approved for use in the United States and the European Union in 2000. In December 2013, Lupin Limited launched a generic version of abacavir/lamivudine/zidovudine.